source
- Biomarker-directed therapies reshape GI cancer treatment, says expertIn a recent OncLive On Air podcast, host Courtney Flaherty spoke with Dr. Michael J. Pishvaian about the growing role of biomarker-directed strategies in gastrointestinal oncology. Dr. Pishvaian n…
- FDA approves Zenocutuzumab for NRG1 fusion-positive advanced cholangiocarcinomaThe U.S. Food and Drug Administration has granted approval for zenocutuzumab-zbco, marketed as Bizengri, to treat adult patients with NRG1 fusion‑positive advanced, unresectable or metastatic chola…